NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · HSIC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Henry Schein, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Henry Schein, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of $1.36. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Henry Schein, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 5, 2025 |
| $1.15+3.6% vs estimate |
| $3.17B-1.51% vs estimate |
| Q4 2024 | Feb 25, 2025 | $1.19-3.25% vs estimate | $3.19B-3.14% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | $1.22+5.17% vs estimate | $3.17B-5.6% vs estimate |
|---|
THE ANALYST VIEW
34 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $95.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$980.88+$20.32 (+2.12%)
McKesson Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.79% below the high.
$330.53+$6.18 (+1.91%)
Cencora, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.45% below the high.
$251.09+$6.33 (+2.59%)
Cardinal Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.13% below the high.
$24.61+$0.67 (+2.8%)
Envista Holdings Corp’s quoted price sits in the upper half of its reported 52-week range, 19.1% below the high.
$9.61+$0.17 (+1.8%)
DENTSPLY SIRONA Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.89% below the high.
